Genmab A/S (NASDAQ:GMAB) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Genmab A/S (NASDAQ:GMAB) have received an average recommendation of “Moderate Buy” from the twelve brokerages that are covering the company, Marketbeat reports. Four research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $42.17.

Several equities research analysts have issued reports on the company. BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price for the company in a research note on Thursday, February 13th. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research note on Thursday, January 23rd. Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. Finally, Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th.

Genmab A/S Stock Performance

NASDAQ:GMAB opened at $24.14 on Wednesday. Genmab A/S has a one year low of $18.64 and a one year high of $31.88. The stock has a market cap of $15.98 billion, a PE ratio of 13.87, a P/E/G ratio of 2.65 and a beta of 0.98. The stock has a 50 day moving average price of $21.28 and a 200 day moving average price of $22.62.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, analysts predict that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Institutional investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. grew its stake in shares of Genmab A/S by 94.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock valued at $636,000 after buying an additional 12,654 shares in the last quarter. AIMZ Investment Advisors LLC purchased a new position in Genmab A/S in the fourth quarter valued at $3,525,000. HighTower Advisors LLC purchased a new position in Genmab A/S in the third quarter valued at $273,000. Verition Fund Management LLC purchased a new position in Genmab A/S in the third quarter valued at $709,000. Finally, Natixis Advisors LLC boosted its holdings in Genmab A/S by 29.8% in the third quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock valued at $5,036,000 after purchasing an additional 47,437 shares during the period. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.